Heron Therapeutics Inc., a commercial-stage biotechnology company focused on improving the lives of patients by developing treatments to address important unmet patient needs, has appointed Brett Fleshman as Chief Business Officer.   Fleshman has 25 years of experience in corporate and business development, commercial strategy, and marketing of pharmaceuticals, biologics, and surgical devices.   “Now is the right time to add substantial BD and M&A experience to the management team ...